Calder Biosciences
Preclinical-stage biotechnology company developing site-specific covalent crosslinking and structure-based protein design methods to stabilize viral surface protein subunit immunogens. Programs target RSV, a headless-HA influenza immunogen, and Epstein-Barr virus envelope proteins. Reported activities include platform R&D, preclinical immunogenicity and challenge studies, bioprocess and CMC development, technology transfer to clinical CDMOs, IP generation, and execution of government- and foundation-funded programs.
Industries
Nr. of Employees
small (1-50)
Calder Biosciences
7 Penn Plaza, 9th Fl, New York, NY 10001; additional operational address: 140 58th Street, Bldg A, Unit 8J, Brooklyn, NY 11220
Patents
Compositions and methods for vaccination against respiratory syncytial virus infection
US-11623004-B2
View Details
Compositions and methods for vaccination against respiratory syncytial virus infection
US-11623004-B2
View DetailsProducts
Stabilized RSV prefusion F subunit immunogen
Soluble RSV F (prefusion) subunit immunogen engineered using site-specific covalent crosslinking to preserve prefusion structure, increase thermostability, and elicit neutralizing antibody responses for older adult and maternal formulations.
Headless hemagglutinin (HA) stalk subunit immunogen with crosslink stabilization
HA stalk-focused influenza immunogen produced by removing the head domain and stabilizing the stalk via targeted covalent crosslinks to focus immune responses on conserved epitopes for broader strain coverage.
Stabilized EBV envelope subunit immunogens
Engineered EBV immunogens based on gp350 and the gB/gH-gL envelope complex stabilized via targeted crosslinking to preserve functional prefusion conformations and elicit neutralizing responses.
Stabilized RSV prefusion F subunit immunogen
Soluble RSV F (prefusion) subunit immunogen engineered using site-specific covalent crosslinking to preserve prefusion structure, increase thermostability, and elicit neutralizing antibody responses for older adult and maternal formulations.
Headless hemagglutinin (HA) stalk subunit immunogen with crosslink stabilization
HA stalk-focused influenza immunogen produced by removing the head domain and stabilizing the stalk via targeted covalent crosslinks to focus immune responses on conserved epitopes for broader strain coverage.
Stabilized EBV envelope subunit immunogens
Engineered EBV immunogens based on gp350 and the gB/gH-gL envelope complex stabilized via targeted crosslinking to preserve functional prefusion conformations and elicit neutralizing responses.
Expertise Areas
- Protein engineering for vaccine immunogens
- Recombinant subunit vaccine development
- Bioprocess development, CMC and technology transfer to CDMOs
- Preclinical immunogenicity and viral challenge studies
Key Technologies
- Site-specific covalent crosslinking (dityrosine)
- Structure-based protein design
- Recombinant protein expression (mammalian cell systems)
- Upstream cell culture and downstream purification (chromatography, TFF)
News & Updates
Peer-reviewed publication demonstrating engineered dityrosine bonding improves stability and potency of RSV prefusion F immunogens.
Peer-reviewed publication demonstrating engineered dityrosine bonding improves stability and potency of RSV prefusion F immunogens.